Wells Fargo’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Wells Fargo’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,300	Closed	-$23K	–	8076
2021 Q4	$23K	Buy	+1,300	New	+$27.4K	﹤0.01%	6294

Wells Fargo's KNTE Position: Q2 2024 in Review

Wells Fargo sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 144 shares — an estimated $383 sold.

Wells Fargo first reported a position in KNTE in Q1 2021 and held it in 12 quarters. The position peaked at $211K in Q4 2021. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

Wells Fargo reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Wells Fargo sold 144 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $383.
Wells Fargo first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 12 quarters.
Wells Fargo's Kinnate Biopharma Inc. Common Stock position peaked at $211K in Q4 2021.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.